Premium
Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions
Author(s) -
Okumura Yoshihide,
Murase Takayuki,
Saida Kosuke,
Fujii Kana,
Takino Hisashi,
Masaki Ayako,
Ijichi Kei,
Shimozato Kazuo,
Tada Yuichiro,
Nibu Kenichi,
Inagaki Hiroshi
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24856
Subject(s) - mucoepidermoid carcinoma , medicine , grading (engineering) , perineural invasion , histology , carcinoma , surgery , oncology , cancer , gastroenterology , civil engineering , engineering
Background The National Comprehensive Cancer Network (NCCN) guidelines recommend considering postoperative radiotherapy (PORT) for completely resected T1/2N0M0 salivary mucoepidermoid carcinomas when they show tumor spillage, perineural invasion, or intermediate/high‐grade histology. CRTC1/3‐MAML2 fusions have been associated with a favorable clinical outcome. Methods Forty‐seven T1/2N0M0 mucoepidermoid carcinoma cases positive for CRTC1/3‐MAML2 fusions were completely resected and were not treated with PORT. Results Pathologically, none of the cases showed tumor spillage or perineural invasion. Cases with intermediate/high‐grade histology numbered 9 (19%) to 26 (55%) with the currently used 3 different grading systems. During the follow‐up (median 60 months), locoregional tumor recurrence occurred in 4 cases, which were treated with surgery alone. At the last follow‐up (median 60 months; 7‐160), all patients were alive with no evidence of disease. Conclusion An excellent prognosis may be achieved without PORT in T1/2N0M0 mucoepidermoid carcinoma patients positive for CRTC1/3‐MAML2 fusions when the tumors are completely resected without tumor spillage.